SGTX Sigilon Therapeutics Inc.

9.15
-0.74  -7%
Previous Close 9.89
Open 9.9
52 Week Low 9.01
52 Week High 54.3167
Market Cap $288,496,325
Shares 31,529,653
Float 18,811,506
Enterprise Value $187,726,466
Volume 381,105
Av. Daily Volume 142,873
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SIG-001
Hemophilia A
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity…

    New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity to Tessera's Board of Directors," said Geoffrey von Maltzahn, Ph.D., CEO and Co-Founder of Tessera. "Elliott has overseen more than a dozen new medications on their way to market, and Mary has guided major strategic, fundraising, and partnership efforts. Together, they offer decades of experience that will help us rapidly grow Tessera and to fulfill our mission of curing diseases by writing in the code of life."

    "The next frontier in medicine will be therapeutics that cure and provide enduring protection against disease. I am excited to welcome Elliott and Mary to the team at Tessera and look forward to working closely with them as we advance Tessera's Gene Writing platform and pioneer the future of genetic medicine," said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board, Tessera and CEO of Flagship Pioneering.

    Dr. Sigal brings decades of clinical experience in drug discovery, drug development, and corporate strategy to Tessera's Board of Directors. He currently serves as a senior advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for Adaptimmune Therapeutics, Surface Oncology, Vir Therapeutics, and Affinia. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. He previously served on the Board of Directors for the gene therapy company, Spark Therapeutics. Dr. Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as the company's Chief Scientific Officer and President of R&D from 2004 until 2013. Under his leadership, fourteen new medicines came to market in multiple therapeutic areas including virology, oncology, immunology, psychiatry, metabolic diseases and cardiovascular disease. During his tenure, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal received his M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school, he received his B.S., M.S., and Ph.D. in Industrial Engineering from Purdue University.

    "Tessera's Gene Writing technology represents a major breakthrough in the field with potential to fundamentally change the future of medicine across many therapeutic areas," said Dr. Elliott Sigal. "I am honored to join the Board and look forward to helping guide the company through continued growth and innovation."

    Dr. Rozenman brings more than 15 years of scientific expertise, company building, and transactions leadership in the biotech industry to Tessera's Board of Directors. She serves as the CFO and CBO of insitro, leading strategic and operational finance and accounting strategy, business development, investor relations, corporate communications, as well as project and portfolio management. Prior to insitro, Dr. Rozenman served as the Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she oversaw business development and partnerships with companies including Regeneron/Sanofi and Nestle Health Science and supported the company's strategic finance and investor relations efforts. Across her time at both insitro and Aimmune, Dr. Rozenman has raised more than $1 billion in capital through a range of public and private transactions, including leadership of Aimmune's IPO in 2015. She received her Ph.D. in Organic Chemistry and Chemical Biology from Harvard University and her B.A. in Biochemistry and Russian Literature from Columbia University.

    "Tessera is pioneering Gene Writing at a pivotal moment for drug discovery, as we rapidly expand our understanding of the genetic drivers of disease. Tessera's work to write into the genome may open opportunities to cure and prevent a broad range of diseases. I am thrilled to join the Board during such an exciting time in the company's growth and look forward to partnering with Geoff and the world class Tessera team," said Dr. Mary Rozenman.

    For more information on Tessera, including how Gene Writing works, partnership opportunities, and job openings, visit www.tesseratherapeutics.com.

    About Tessera Therapeutics

    Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ:AXLA), Codiak BioSciences (NASDAQ:CDAK) Denali Therapeutics (NASDAQ:DNLI), Evelo Biosciences (NASDAQ:EVLO), Foghorn Therapeutics (NASDAQ:FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer (CSO). Most recently, Dr. Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies, Inc., where he was responsible for preclinical development of cell therapies, biologic and small molecule platform technologies to treat neurodegenerative diseases.

    "We are excited to announce the addition of Philip to our leadership team. He is a highly regarded scientific leader, and we believe his experience in cell…

    CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer (CSO). Most recently, Dr. Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies, Inc., where he was responsible for preclinical development of cell therapies, biologic and small molecule platform technologies to treat neurodegenerative diseases.

    "We are excited to announce the addition of Philip to our leadership team. He is a highly regarded scientific leader, and we believe his experience in cell therapy and successful track record of developing platform technologies will be tremendous assets," said Rogerio Vivaldi, M.D., President and CEO of Sigilon. "He's joining us at an important time for the Company as we strategically advance our growing pipeline of novel therapeutics for the treatment of a wide range of chronic diseases. The breadth and depth of Philip's experience will be instrumental in helping us leverage the modularity of our Shielded Living Therapeutics™ platform as we advance multiple programs."

    Dr. Ashton-Rickardt joined AZTherapies in 2019 in connection with its acquisition of Smith Therapeutics, a private company founded by Dr. Ashton-Rickardt to develop a cutting-edge technology platform that he invented using modified T cells designed to restore a healthy balance of inflammatory and regulatory cells in the brain. Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women's Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago. He was awarded tenure by The University of Chicago and is the recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton. He has published more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology), has served as an editor for several academic journals, and has been a member of grant review boards globally. Dr. Ashton-Rickardt earned a B.Sc. in Biochemistry from the University of London, King's College and a Ph.D. in Molecular Biology from the University of Edinburgh.

    Added Dr. Ashton-Rickardt: "I am thrilled to be joining this talented team. I look forward to exploring the potential of this novel platform technology in hopes of further expanding Sigilon's robust pipeline and delivering on its commitment to improve the lives of patients living with chronic diseases."

    About Sigilon Therapeutics

    Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

    Forward-Looking Statements

    This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters, including the modularity of our platform technology and the potential benefits of our pipeline and product candidates. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that we have incurred significant losses since inception and our need for additional funding; the SLTx platform consists of novel technologies that are not yet clinically validated for human therapeutic use; that we have only any results from the testing of any of our product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials; we may be unable to obtain and maintain patent protection and other intellectual property rights for SIG-001 or any other product candidates and for our SLTx platform, or the scope of the patent and other intellectual property protection obtained may not be sufficiently broad; and the risks identified under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the period ended March 31, 2021 and in any subsequent filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.  Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Investor Contacts

    Rob Windsor

    Sigilon Therapeutics, Head of Investor Relations



    617-586-3837

    Mike Biega

    Solebury Trout



    617-913-8890

    Media Contact

    Amy Bonanno

    Solebury Trout



    914-450-0349



    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    "At Flagship Pioneering, we are re-imagining how to prevent and treat disease, feed a growing population, and sustain our planet. We do this by harnessing chemistry, biology, and machine learning/AI to build cohesive, integrated platforms, each with the potential for multiple transformative products," said Noubar Afeyan, Ph.D., Founder and Chief Executive Officer of Flagship Pioneering. "There is no better example of the power of bioplatform companies than Flagship-founded Moderna, which was able to rapidly shift its focus in 2020 to develop, test, and deploy its COVID-19 vaccine in record time."

    Dr. Afeyan continued, "In the last year alone, breakthroughs at Rubius Therapeutics, Denali Therapeutics, Seres Therapeutics, and others demonstrated the exponential impact bioplatforms can have on health. Biotechnology is at the leading edge of technological progress, challenging us to think beyond incremental advances and take big leaps – and Flagship Pioneering is focused on actively leaping to the scientific spaces ripe for disruption."

    Financial Update

    After Fund VII's close, Flagship is now operating with an aggregate capital pool of $6.7 billion, with $14.1 billion assets under management. Over the past four quarters, Flagship deployed $370 million in capital to its companies, combined with more than $4.4 billion from other capital providers, for a total of $4.8 billion in new capital fueling Flagship companies.

    "We are grateful to our longstanding Limited Partners and our new investors for their support as we pioneer life science solutions to tackle the world's most urgent issues," said Stephen Berenson, Managing Partner, Flagship Pioneering. "This expanded capital pool will enable us to support first-in-category platform companies, spanning human therapeutics, agriculture, and nutrition, as well as our soon-to-be-launched Preemptive Medicine and Health Security Initiative, and the development of a robust pipeline of clinical assets through our Pioneering Medicines Division."

    Driving Ground-breaking Multi-Product Bioplatforms                                      

    Flagship Pioneering is dedicated to exploring and innovating in uncharted spaces, as well as founding, launching, and advancing new companies to develop and commercialize these innovations.

    "The biological century is an era of new possibility. Today, the opportunity to harness biology for the benefit of humanity and the world is unprecedented," said Doug Cole, M.D., Managing Partner, Flagship Pioneering. "At Flagship, we challenge ourselves daily to discover what is not yet visible, invent what has previously not been possible, and imagine and realize new ways to treat, cure, diagnose, and prevent diseases."

    Flagship's team of entrepreneurial scientists, executives, and operations experts, as well as its companies, achieved important milestones in the last year, as follows:

    • Unveiled Generate Biomedicines, Invaio Sciences, Inzen Therapeutics, Laronde, and Valo Health
    • Raised $1.8 billion in private investments for early growth-stage companies: Cellarity, Inari Agriculture, Indigo Ag, Invaio Sciences, Omega Therapeutics, Repertoire Immune Medicines, Ring Therapeutics, Senda Biosciences, Tessera Therapeutics, and Valo Health
    • Completed Initial Public Offerings at Codiak Biosciences (NASDAQ:CDAK), Foghorn Therapeutics (NASDAQ:FHTX), Sana Biotechnology (NASDAQ:SANA), and Sigilon Therapeutics (NASDAQ:SGTX)
    • Raised follow-on public market capital in Axcella (NASDAQ:AXLA), Codiak Biosciences (NASDAQ:CDAK), Evelo (NASDAQ:EVLO), Kaleido (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius (NASDAQ:RUBY), and Seres (NASDAQ:MCRB)
    • Conducted more than 60 new explorations, the first step of our company origination process
    • Filed more than 300 patent applications from Flagship Labs
    • Flagship ecosystem companies have 53 clinical programs and 150 pre-clinical programs currently underway

    Assembling a World-Class Team

    Flagship is committed to bringing on the highest caliber industry executives with track records of exceptional performance, as evidenced in the company's new hires over the past year. These have included the recent additions of Christopher P. Austin, M.D., as CEO-Partner, Ara Darzi, M.D., as Chair, Preemptive Medicine and Health Security Initiative, Michael T. Nally, as CEO-Partner and CEO of Generate Biomedicines, and Louisa Salter-Cid, Ph.D., as Chief Scientific Officer for Pioneering Medicines. In addition, Flagship has hired a number of world class executives, scientists, and operations leaders to roles across the company and its ecosystem of companies. 

    Introducing Preemptive Medicine and Health Security, a New, More Comprehensive Approach to Health Security

    Flagship is actively building a division tasked with pioneering a new field that aims to protect, maintain, or improve people's health before they get sick by proactively intervening in those who are seemingly healthy but at risk. It will encompass interventions that protect health from external threats (health security) as well as to prevent or delay the onset of disease (preemptive health) to better prepare for the next infectious disease threats, and to pursue bolder treatments for existing pandemic diseases such as obesity, cancer, and neurodegeneration. Learn more about Flagship's perspective in this recent whitepaper, "Health Security and Beyond: A New Paradigm for a Post-Pandemic World."

    "The pandemic has laid bare the critical nature of health, not only to individuals, but to economies and societies," said Ara Darzi, M.D., Chair of Flagship's Preemptive Medicine and Health Security Initiative. "Flagship is pioneering a new field that aims to protect, maintain, and improve people's health by providing security against threats for everyone, and preventing or postponing the onset of disease for 'seemingly healthy' people, before they experience any recognisable symptoms at all."

    Building the Pioneering Medicines Division

    Flagship launched its Pioneering Medicines Division earlier this year to harness the power of Flagship's scientific and development innovation to create and advance novel therapeutic medicines that benefit more patients sooner. Given the broad applicability of many Flagship platforms, Pioneering Medicines is focused on expanding the reach of these scientific innovations by creating medicines in disease areas where the companies are not yet focused and working across platforms in unprecedented ways.

    "Pioneering Medicines is focused on innovative approaches to achieving greater impact for patients at faster speeds," said Paul Biondi, Executive Partner, Flagship Pioneering and President of Pioneering Medicines. "We are leveraging the innovative scientific platforms and technologies within Flagship Pioneering's ecosystem of companies to conceive and develop a unique portfolio of life-changing treatments for patients."

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ:DNLI), Indigo Ag, Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Valo Health.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flagship-pioneering-closes-3-4-billion-capital-pool-to-drive-continued-breakthrough-innovations-in-human-health-and-sustainability-301311419.html

    SOURCE Flagship Pioneering

    View Full Article Hide Full Article
  4. CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the Jefferies Virtual Healthcare Conference. The fireside chat will take place on Thursday, June 3 at 8:00 a.m. EDT, in a virtual format.

    A live webcast of the fireside chat will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the fireside chat will be available at the same location following the event…

    CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the Jefferies Virtual Healthcare Conference. The fireside chat will take place on Thursday, June 3 at 8:00 a.m. EDT, in a virtual format.

    A live webcast of the fireside chat will be accessible under "Events and Presentations" in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the fireside chat will be available at the same location following the event.

    About Sigilon Therapeutics

    Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

    Investor Contacts

    Rob Windsor

    Sigilon Therapeutics, Head of Investor Relations

     

    617-586-3837

    Mike Biega

    Solebury Trout

     

    617-913-8890

    Media Contact

    Amy Bonanno

    Solebury Trout

     

    914-450-0349



    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.

    "Our ambition is to build the most impactful and valuable crop health company on the planet," said Ignacio Martinez, Co-Founder and CEO of Invaio. "The world is changing quickly, and food production practices must adapt to keep pace with evolving consumer demands, changing environmental conditions and increased stress on ecological resources."

    "This commitment by new and existing investors enables Invaio to accelerate the expansion of our integrated technology platforms that will solve performance and delivery challenges facing the agriculture industry. Our approach to reducing the use of fertilizers and chemicals will revolutionize the industry and guide the production of food to biological practices in less than a decade," explained Martinez.

    Teeming with pioneering technologies, extraordinary talent, and an insurgent mindset, Invaio Sciences has focused research and development in large addressable perennial, row crop and vegetable marketplaces. With this most recent financing, Invaio will continue to delve deep into diverse areas of discovery including tree nutritional health, insect management, vector and disease control, transformative herbicides and fungicides replacements, advanced seed technologies, carbon cycling, and more.

    "This is an exciting time to be in agricultural science. Within the next decade, a new playbook for producing food will evolve and take root, and Invaio is at the forefront of this discovery, actively contributing to developing the model for agricultural production of the future," said Gerardo Ramos, Chief Science Officer, Invaio Sciences. "At Invaio, we take a systems approach: controlling the disease with minimal environmental impact by reducing the use of pesticides by more than 90 percent and increasing carbon capture while improving the health of the system as a whole. This is just the beginning."

    Already addressing some of the biggest concerns plaguing crop health throughout the planet, Invaio Sciences is gaining a foothold within perennial production. Resources from the Series C capital raise will immediately be used to roll out solutions for problems including HLB in the citrus industry, Xylella in Olive production, and to institute more refined practices in managing vineyards and orchards. Invaio is also advancing a new carbon offering for perennial producers and is working with the USDA to bolster the vitality of beehives through ensuring pollinator health and the longevity of flowering real food trees in the future.

    "Invaio is transitioning from an R&D-focused organization to a fully commercial enterprise," commented Peleg Chevion, President and Chief Commercial Officer of Invaio. "We're building an economically attractive approach to institute sustainable agriculture at scale for diverse growers around the world."

    Chevion continued, "We are deeply committed to delivering the right solutions for producers now, as well as taking a generational view of their operations and the entire value chain. Our use of precision delivery offers a cleaner, safer and more mindful approach to manage the need for healthier crops and more nutritious and efficient food production in the future."

    About Invaio Sciences:

    Invaio Sciences is a multi-platform technology company that unlocks the potential of the planet's interdependent systems to address pressing agricultural, nutritional, and environmental challenges. Founded by Flagship Pioneering in 2018, Invaio leverages discoveries from diverse fields including human therapeutics, agriculture, environmental science, and advanced manufacturing. The company's deep understanding of the physiology of insects, plants and trees, together with its novel integrated solutions approach, promises to refine agricultural practices and reduce the need for pesticides globally. Invaio Sciences is dedicated to developing solutions that are mindful of beneficial insects, bad for pests, and safer for us all.  For more information, please visit www.invaio.com

    About Flagship Pioneering:

    Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $80 billion in aggregate value. To date, Flagship has deployed over $2.3 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Inari Agriculture, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invaio-sciences-raises-88-9-million-to-accelerate-the-transition-to-biological-agriculture-301298364.html

    SOURCE Invaio Sciences

    View Full Article Hide Full Article
View All Sigilon Therapeutics Inc. News